Zeitschrift für Rheumatologie

, Volume 64, Issue 1, pp 12–17 | Cite as

Kardiovaskuläre Manifestationen bei entzündlich-rheumatischen Erkrankungen

BEITRAG ZUM SCHWERPUNKTTHEMA

Zusammenfassung

Erste Zusammenhänge von Herzbeteiligungen und entzündlich-rheumatischen Erkrankungen wurden schon Ende des 19. Jahrhunderts beschrieben, wobei seither Myoperikarditiden und Endokarditiden am häufigsten dokumentiert wurden. Entzündlich-rheumatische Erkrankungen können teils mit unterschiedlicher Häufigkeit zu einer Herzbeteiligung mit erhöhter kardiovaskulärer Mortalität führen bei derzeit nicht bekannten Ursachen.

Ziel dieser Übersichtsarbeit ist eine Darstellung möglicher kardiovaskulärer Symptome bei unterschiedlichen entzündlich-rheumatischen Krankheitsbilder für eine effiziente differentialdiagnostische Einordnung und Abklärung im rheumatologischen Praxisalltag.

Schlüsselwörter

Kardiovaskuläre Manifestationen  entzündlich-rheumatische Erkrankungen 

Cardiovascular manifestations in inflammatory rheumatic diseases

Summary

First descriptions about cardiovascular manifestations (mostly myocarditis and endocarditis) in inflammatory rheumatic diseases were dated at the end of the 19th century. Inflammatory rheumatic diseases show an increased cardiovascular manifestation and mortality, but the reasons for this are unknown. This overview presents the current knowledge about cardiovascular manifestations in different inflammatory rheumatic diseases for an efficient differential diagnostic and clarification in the daily practice.

Key words

Cardiovascular manifestations inflammatory rheumatic diseases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Al-Herz A, Ensworth S, Shojana K, Esdaile JM (2003) Cardiovascular disease risk factor screening in systemic lupus erythematosus. J Rheumatol 30:493–496Google Scholar
  2. 2.
    Anavari A, Graninger W, Schneider B et al (1992) Cardiac involvement in systemic sclerosis. Arthritis Rheum 35:1356–1361Google Scholar
  3. 3.
    Bergfeldt L (1997) HLA-B27-associated cardiac disease. Ann Intern Med 127(8 Pt 1):621–629PubMedGoogle Scholar
  4. 4.
    Bonfiglio T, Atwater EC (1969) Heart Disease in patients with seropositive rheumatoid arthritis. Arch Intern Med 124:714–719Google Scholar
  5. 5.
    Bulkley BH, Roberts WC (1973) Ankylosing spondylitis and aortic regurgitation. Description of characteristic cardiovascular lesions from study of eight necropsy patients. Circulation 48(5):1014–1027Google Scholar
  6. 6.
    Charles EW, Barron T, Lowrimore G et al (1985) Cardiac Sarcoidosis: Two Cases with Ventricular Tachycardia and Review of Cardiac Involvement in Sarcoid. Texas Heart J 12:377–383Google Scholar
  7. 7.
    Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324:1149–1155Google Scholar
  8. 8.
    Crawford MH, Sergent J (1998) Cardiopulmonary symptoms in rheumatic disease. In: Klippel HJ, Dieppe PA (Hrsg) Rheumatology. Second edition, Vol. 1. Mosby International, London, England 2:7.1–7.8Google Scholar
  9. 9.
    Delgado AJ, Ames PR, Donohue S et al (2002) Antibodies to high-density lipoprotein and beta-2-glykoprotein I are inversely correlated with paraxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694Google Scholar
  10. 10.
    Genth E (2001) Arthritis psoriatica und Arthritiden bei gastrointestinalen Erkrankungen. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, Springer, Berlin Heidelberg, Kapitel 44, S 662–673Google Scholar
  11. 11.
    Ghosh P, Fleming GA, Stovin PGI (1972) Myocardial sarcoidosis. Br Heart J 34:769–773Google Scholar
  12. 12.
    Haagsma CJ, Blom HJ, van Riel PLCM et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79–84PubMedGoogle Scholar
  13. 13.
    Hellemanns S, Dens J, Knockaert D (1997) Coronary involvement in the Churg-Strauss syndrome. Heart 77:567–578Google Scholar
  14. 14.
    Henke R, Allouch V, Häntzschel H (1992) Herzbeteiligung. In: Häntzschel H, Otto W, Nassonova V (Hrsg) Rheumatoid-Arthritis—eine systemische Erkrankung. JA Barth, Leipzig, S 150–153Google Scholar
  15. 15.
    Herzer P (2000) Lyme-Borreliose. In: Miehle W, Fehr K, Schattenkirchner M, Tillmann K (Hrsg) Rheumatologie in Praxis und Klinik. Thieme, Stuttgart New York, S 742–751Google Scholar
  16. 16.
    Jung O, Stapfer G, Ditting T, Geiger H, Lange U (2004) Pathologic alterations of the heart and the kidney in patients with ankylosing Spondylitis. Clin Exp Rheumatol 22:666Google Scholar
  17. 17.
    Kabakov AE, Tertov VV, Saenko VA et al (1992) The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunpathol 63:214–220Google Scholar
  18. 18.
    Kahl LE (1992) The spectrum of pericardial tamponade in systemic lupus erythematosus: Report of ten patients. Arthritis Rheum 35:1343–349Google Scholar
  19. 19.
    Kato H, Sugimura T, Akagi T et al (1996) Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94:1379–1385Google Scholar
  20. 20.
    Kawasaki T (1967) Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Aerugi 16:178–222Google Scholar
  21. 21.
    Khamashta MA, Cervera R, Asherson RA et al (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335:1541–1544Google Scholar
  22. 22.
    Khan MA (1998) Ankylosing Spondylitis: clinical features. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edition, pp 6.16.1–6.16.10Google Scholar
  23. 23.
    Lange U, Teichmann J (2003) Whipple arthritis: diagnosis by molecular analysis of synovial fluid—current status of diagnosis and therapy. Rheumatology 42:473–480Google Scholar
  24. 24.
    Lautermann D (2002) Kardiovaskuläre Manifestationen bei Spondylitis ankylosans. In: Braun J, Sieper J (Hrsg) Spondylitis ankylosans. Uni-Med, Bremen, London, Boston, S 130–135Google Scholar
  25. 25.
    Lehman TJA, Palmeri ST, Hastings C, Klippel JH et al (1983) Bacterial endocarditis complicating systemic lupus erythematosus. J Rheum 10:655–658Google Scholar
  26. 26.
    Lethinen K (1980) Cause of death in 79 patients with ankylosing spondylitis. Scand J Rheumatol 9(3):145–147Google Scholar
  27. 27.
    Liebscher KM, Weise R, Henßge R et al (1986) Herzbeteiligung bei Rheumatoid-Arthritis. Zsch ges inn Med 41:634–636Google Scholar
  28. 28.
    Liuzzo G, Goronzy JJ, Yang H et al (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 102:2883–2888Google Scholar
  29. 29.
    Logar D, Kveder T, Rozman B, Dobovisek J (1990) Possible association between anti-Ro antibodies and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 49:627–629PubMedGoogle Scholar
  30. 30.
    Märker-Hermann E, Mayet WJ (2001) Organsymptome. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, Springer, Berlin Heidelberg, Kapitel 19, S 266–280Google Scholar
  31. 31.
    Manger K, Kusus M, Forster C, Ropers D, Daniel WG, Kalden JR, Achenbach S, Manger B (2003) Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 62:846–850Google Scholar
  32. 32.
    Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415Google Scholar
  33. 33.
    Mikuls TR, Saag KG (2001) Comorbidity in rheumatoid arthritis. In: O’Dell JR (ed) Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, Vol. 27, No. 2. WB Saunders, pp 283–297Google Scholar
  34. 34.
    Niksic F, Burmucic K, Kullich W, Klein G (2002) Kardiovaskuläre Manifestationen bei entzündlich rheumatischen Erkrankungen. Wien Med Wschr 152:220–222Google Scholar
  35. 35.
    Pasceri V, Yeh ETH (1999) A tale of two diseases—atherosclerosis and rheumatoid arthritis. Circulation 100:2124–2130Google Scholar
  36. 36.
    Porter GH (1951) Sarcoid heart disease. N Engl J Med 26:1350–1357Google Scholar
  37. 37.
    Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive Protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMedGoogle Scholar
  38. 38.
    Roldan CA, Shively BK, Crawford MH (1996) An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335:1424–1430Google Scholar
  39. 39.
    Saravana S, Gillott T (2004) Ischaemic heart disease in rheumatoid arthritis patients. Rheumatology, 43:113–114Google Scholar
  40. 40.
    Schmidt KL (2000) Checkliste Rheumatologie. Thieme, Stuttgart New YorkGoogle Scholar
  41. 41.
    Sukenik S, Pras A, Buskila D et al (1987) Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol 6(4):588–592Google Scholar
  42. 42.
    Torzewski M, Torzewski J, Bowyer DE et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18:1386–1392Google Scholar
  43. 43.
    Turesson C, Jacobsson S, Berström U (1999) Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology 38:668–674Google Scholar

Copyright information

© Steinkopff Verlag 2005

Authors and Affiliations

  1. 1.Kerckhoff-Klinik, Abteilung RheumatologieBad NauheimGermany

Personalised recommendations